Biological Age Tests: What They Measure—and What They Cannot Tell You

A report can make biological age look deceptively simple: one number, one comparison with your birthday, and perhaps a colored arrow pointing toward “younger.” The more useful starting point is not whether the number is flattering. It is what the test was designed to tell you.

Consider three different promises: “We can measure a biological pattern,” “That pattern is associated with later health,” and “Using this result to choose care improves health.” Each promise requires its own evidence. They should not be treated as interchangeable. [4,10]

What is inside the number?

An epigenetic clock combines selected DNA methylation signals in a mathematical model. It does not directly read the remaining lifespan of your heart, brain, or whole body. The original multi-tissue clock demonstrated that age-related methylation patterns could be used to estimate age; subsequent approaches have pursued different targets. [1,3]

For example, DunedinPACE was developed to capture a pace of biological change. A rate is not the same kind of result as an estimated age in years. Comparing them as though both measure “how old you really are” loses an essential distinction. [2]

When reviewing a report, ask for the method name, version, specimen type, intended use, and reference population. A general label such as “advanced longevity analysis” is not an explanation of the measurement.

Predictive information can be useful without being destiny

Observational research has connected some epigenetic measures with later outcomes, including mortality. A 2026 analysis in the German BASE-II cohort adds to that evidence. It does not establish that a testing-guided plan improves survival, or that the same performance applies to every age group and setting. [9]

This distinction is not an argument against innovation. It is a way to identify what the next study needs to establish. A marker may be useful in research before there is a clear reason to use it routinely in an individual visit. [3]

A trial can change a clock without proving rejuvenation

The DO-HEALTH epigenetic analysis examined 777 older adults over three years. It reported small changes in selected clocks with omega-3, with an additional combined-intervention signal for one clock. This was a post-hoc biomarker analysis, not proof that a supplement prescription reverses aging or adds years of life. [7]

A broader 2026 comparison across heterogeneous intervention studies likewise showed that different clocks respond differently. Responsiveness is a research finding; a clinically meaningful benefit cannot simply be read from the size of the score change. [8]

The FDA's explanation of surrogate endpoints provides a helpful general principle: a biological measurement becomes a substitute for clinical benefit only when sufficient evidence supports that use. A favorable laboratory change alone does not settle the question. This principle is not a statement about the regulatory status of any particular commercial age test. [10]

Precision is part of interpretation

Technical noise can affect epigenetic age estimates, and reliability differs among algorithms. Research has developed methods to improve consistency, but this does not justify assigning one universal error range to all reports. [5]

Imagine an explicitly hypothetical comparison: a person changes laboratories and receives a lower age estimate. Before calling that improvement, the report would need to clarify whether the same biological measure and calculation were used. Even a comparable difference needs an interpretation, not just a congratulatory graphic.

Useful reporting should make it possible to ask: “How much change can occur without a meaningful change in health?” and “Is there evidence that the difference observed here should alter my care?” The aim is not to demand impossible certainty, but to identify uncertainty rather than hide it.

Before purchasing: ask what happens after the result

My suggested decision check is practical rather than numerical. Write down the question you hope the test will answer. Then ask the service to describe the possible results and what action each would support. Request evidence for the action itself, not only for the technology used to produce the score.

Ask separately about specimen storage, data retention, research use, and whether additional purchases are part of the proposed follow-up. You should be able to understand the intended experience before committing to a recurring package.

An independent question is particularly useful: Would this recommendation still make sense if I had never taken the age test? If the proposed plan cannot be explained without repeatedly pointing to the score, the underlying clinical reasoning deserves clarification.

If you already have a result

Bring the complete report rather than a screenshot of its headline. Explain why you ordered it, what worries you, and what has actually changed in your daily life. Treat “What should we do with this information?” as an open question rather than an obligation to start something.

A lower estimate is not a reason to dismiss symptoms. A higher estimate should not be turned into a prediction of how long you have left. Test interpretation needs to remain connected to the individual question and the evidence supporting that use. [4]

The useful endpoint is a better decision

MERHI ONE's editorial position is to welcome promising research without turning every promising marker into a personal treatment target. The goal is not to collect the lowest possible number from every available test. It is to understand which information is reliable enough, relevant enough, and actionable enough to improve the conversation about your health.

Evidence before hype. Understanding before action.

Related reading

Muscle, strength and sarcopenia

Brain health after 40

Explore the MERHI ONE newsletter and choose the editions you would like to follow. Registration is open. Newsletter delivery has not yet started. Newsletter

General educational information, not an individualized test recommendation, diagnosis, treatment plan, or substitute for professional care.

References

[1] Horvath S. DNA methylation age of human tissues and cell types. Genome Biology. 2013;14:R115. DOI: 10.1186/gb-2013-14-10-r115. Source. ↩

[2] Belsky DW, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420. DOI: 10.7554/eLife.73420. Source. ↩

[3] Moqri M, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023;186(18):3758–3775. DOI: 10.1016/j.cell.2023.08.003. Source. ↩

[4] Moqri M, et al. Validation of biomarkers of aging. Nature Medicine. 2024;30:360–372. DOI: 10.1038/s41591-023-02784-9. Source. ↩

[5] Higgins-Chen AT, et al. A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking. Nature Aging. 2022;2:644–661. DOI: 10.1038/s43587-022-00248-2. Source. ↩

[7] Bischoff-Ferrari HA, et al. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging. 2025;5:376–385. DOI: 10.1038/s43587-024-00793-y. Source. ↩

[8] Sehgal R, et al. Responsiveness of epigenetic aging biomarkers to longevity interventions in humans. Nature Medicine. 2026;32:3477–3490. Published August 21, 2026. DOI: 10.1038/s41591-026-04562-9. Source. ↩

[9] Vetter VM, et al. Comparing fourteen consensus biomarkers of aging: epigenetic pace of aging as the strongest predictor of mortality in BASE-II. Biomarker Research. 2026;14:37. DOI: 10.1186/s40364-026-00909-z. Source. ↩

[10] U.S. Food and Drug Administration. FDA Facts: Biomarkers and Surrogate Endpoints. Official institutional webpage. Source. ↩